OncLiveIdelalisib Improves Survival in High-Risk CLLOncLiveCombination treatment with the PI3K-delta inhibitor idelalisib and rituximab (Rituxan) was associated with a >70% improvement in overall survival (OS) in patients with high-risk relapsed/ref…
|
Idelalisib plus rituximab boosts survival in relapsed chronic lymphocytic leukemia
The Oncology Report NEW ORLEANS – Adding idelalisib to rituximab significantly extends survival in patients with heavily pretreated relapsed chronic lymphocytic leukemia unsuitable for chemotherapy, according to results from Study 116. The primary endpoint of median … |
Ibrutinib and rituximab trigger 95 percent response rate among CLL patientsHealthCanal.comNearly all of the high-risk chronic lymphocytic leukemia patients in a phase II clinical trial responded to treatment with the targeted therapy ibrutinib and the …
Emergent announces positive results from phase 1b study of otlertuzumab in …pharmabiz.comEmergent BioSolutions Inc., a specialty pharmaceutical company, has reported preliminary results from a phase Ib single-arm, open-label study evaluating the safe…
India.Com HealthTwo-drug combo of rituximab and pidilizumab could help treat cancerIndia.Com Healthdrugs One drug attacks tumor cells directly, the other treats the immune system by taking the brakes off T cell response, and together, they put half of …
Science Codex |
Two-drug combo could help treat cancer
Daily News & Analysis Neelapu said that Rituximab treatment alone usually achieves a 40 percent overall response rate and about 11 percent complete responses, asserting that the side effect profile of the combination is about the same as rituximab alone. He added … Targeted antibody, immune checkpoint blocker rein in follicular lymphomaScience Codex |
|
Targeted antibody, immune checkpoint blocker rein in follicular lymphoma
Medical Xpress “The combination of the established antibody drug rituximab with the experimental drug pidilizumab so far also has a remarkably mild side effect profile,” Neelapu said. Of 29 study participants at a median follow-up of 15.4 months, 19 (66 percent) had … |
|
Idelalisib With Rituximab Boosts Survival in Relapsed CLL
Medscape In a phase 3 trial, known as Study 116, the investigational agent idelalisib (under development by Gilead), when added to rituximab (Rituxan), improved outcomes in patients with relapsed CLL. “Idelalisib is a targeted, highly selective, orally … Idelalisib plus rituximab extended survival in previously treated CLLHealio Idelalisib/Rituximab Combo Improves Survival in Late-Stage CLLCancer Network Gilead’s Pipeline EncouragesYahoo News |
|
Dr. Reddy’s Targets Roche’s Rituxan in Europe: Corporate India
Businessweek Making a version of rituximab, the ingredient in cancer-treatment Rituxan, is where “the big opportunity is in the developed markets, clearly; that’s where the big sales are,” he said. Dr. Reddy’s joins larger rivals including Novartis AG and Pfizer … |
|
New CLL Therapy Beats Standard Protocol
MedPage Today The findings suggest that the new drug is “equally safe yet more powerful” than rituximab, commented Jennifer Brown, MD, PhD, of the Dana-Farber Cancer Institute in Boston, who was not involved in the study but who moderated a press conference at which … |